Nous utilisons des cookies pour optimiser le site internet. En poursuivant votre navigation sur ce site ou en fermant cette fenêtre, vous acceptez notre politique concernant l'utilisation de cookies.

Veuillez noter que cette partie du site n’est disponible qu’en Anglais
Imprimir Partager

Chr. Hansen off to a solid start to the year: 10% organic growth in Q1

Chr. Hansen off to a solid start to the year: 10% organic growth in Q1
Press ReleaseJan 12. 2018 07:04 GMT

Bioprotection continues to show impressive momentum

Chr. Hansen reports strong organic revenue growth of 10% in the first three months of 2017/18: Food Cultures & Enzymes 12%, Health & Nutrition 10% and Natural Colors 4%. EBIT before special items decreased by 1% to EUR 65 million, corresponding to an EBIT margin before special items of 25.4%. The overall outlook for 2017/18 is unchanged.

Read the full report here

Q1 2017/18 results

EUR million Q1
2017/18
Q1
2016/17
Growth
Revenue 254.5 241.7 5%
EBIT before special items 64.7 65.5 (1)%
Profit for the period 46.5 47.0 (1)%
Free cash flow before acquisitions, divestments and special items (18.9) (19.1) 1%
Organic growth, % 10% 11%
Gross margin, % 52.5% 53.4%
EBIT margin before special items, % 25.4% 27.1%
ROIC excl. goodwill, % 30.9% 34.3%

CEO Cees de Jong says: “We have had a solid start to the year, with Food Cultures & Enzymes’ organic growth better than expected. Sales of bioprotective solutions continue to show impressive momentum, and this is still without any significant impact from the second-generation FreshQ® products that we launched at the beginning of this financial year. We have also introduced ProKids®, an innovative product concept for a children’s drinking yogurt containing our LGG® probiotic strain. As expected, organic sales growth in Natural Colors was below our long-term ambition.

"Our EBIT margin before special items in Q1 was lower than last year, mainly due to the sale of a property in Argentina in Q1 2016/17, adverse currency impacts and costs related to starting up our new production capacity in Copenhagen. The new capacity is producing ahead of schedule, and we expect to see improving margins from this toward the end of the financial year.

"We are encouraged by the solid start to the year, and we maintain our overall guidance for the full year. We increase our expectations to organic growth for Food Cultures & Enzymes to be even stronger and above the long term 7-8% growth target that we have for this business. At the same time, we lower our expectations to organic growth in Health & Nutrition for the full year to be below our long term guidance for this business due to the challenging market conditions in North America.”

Outlook for 2017/18

12 January 2018 25 October 2017
Organic revenue growth 8-10% 8-10%
EBIT margin before special items Around 28.9% Around 28.9%
Free cash flow before special items, acquisitions and divestments Around EUR 188 million

Around EUR 188 million 

The guidance for EBIT margin before special items and for free cash flow before acquisitions, divestments and special items assumes constant currencies from the time of this announcement and for the remainder of the financial year.


Chr. Hansen est une entreprise de bioscience internationale qui met au point des solutions naturelles pour les industries des secteurs alimentaire, nutritionnel, pharmaceutique et agricole. Les produits comprennent des cultures, des enzymes, des probiotiques et des colorants naturels ; toutes les solutions s'appuient sur de fortes compétences en matière de recherche et développement, doublées d'investissements significatifs en matière de technologie. Le chiffre d'affaires pour l'exercice 2015/16 est de 949 millions d'euros. La société emploie plus de 2 800 salariés motivés dans 30 pays et les unités de fabrication principales sont implantées au Danemark, en France, aux Etats-Unis et en Allemagne. Chr. Hansen a été fondée en 1874 et est cotée au Nasdaq de Copenhague.

Que recherchez-vous ?

Partager cette page

Selectionner votre langue